Commodore Capital LP recently announced the acquisition of new stake in Enliven Therapeutics Inc (NASDAQ:ELVN). The institutional investor has increased its shareholding in the Healthcare company by 23.57% to 2.9 million shares with purchase of 0.55 million shares. This fresh investment now brings its stake to 7.04% valued currently at $32.67 million. In addition, Citadel Advisors LLC raised its holdings by 55281.0 to 2.35 million shares. And Fairmount Funds Management LLC has lifted its position by 0.32% or 6744.0 shares – to 2.13 million shares.
With over 0.46 million Enliven Therapeutics Inc (ELVN) shares trading Friday and a closing price of $14.85 on the day, the dollar volume was approximately $6.84 million. The shares have shown a negative half year performance of -24.43% and its price on 12/22/23 gained nearly 14.94%. Currently, there are 41.21M common shares owned by the public and among those 19.42M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 44 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 28 of these insider trades were purchases, accounting for 27,304,612 shares. Insider sales of the common stock occurred on 16 occasions, with total insider shares sold totaling 3,275,541 shares.
The top 3 mutual fund holders in Enliven Therapeutics Inc are Vanguard Total Stock Market ETF, Fidelity Advisor Series VII – Bio, and Fidelity Small Cap Growth Fund. Vanguard Total Stock Market ETF owns 0.7 million shares of the company’s stock, all valued at over $7.87 million. Fidelity Small Cap Growth Fund now owns shares totaling to 1.48% of the shares outstanding.
Shares of Enliven Therapeutics Inc (NASDAQ: ELVN) opened at $12.97, up $0.05 from a prior closing price of $12.92. However, the script later moved the day high at 15.41, up 14.94%. The company’s stock has a 5-day price change of 24.79% and 6.91% over the past three months. ELVN shares are trading -9.23% year to date (YTD), with the 12-month market performance down to -8.56% lower. It has a 12-month low price of $9.80 and touched a high of $25.34 over the same period. ELVN has an average intraday trading volume of 122.79K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 28.34%, 25.98%, and -12.38% respectively.
Institutional ownership of Enliven Therapeutics Inc (NASDAQ: ELVN) shares accounts for 49.24% of the company’s 41.21M shares outstanding. Mutual fund holders own 32.51%, while other institutional holders and individual stakeholders account for 40.91% and 16.77% respectively.
It has a market capitalization of $611.97M and a beta (3y monthly) value of 1.03. The stock’s trailing 12-month PE ratio is 65.59, while the earnings-per-share (ttm) stands at $0.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.71% over the week and 9.62% over the month.
Analysts forecast that Enliven Therapeutics Inc (ELVN) will achieve an EPS of -$0.54 for the current quarter, -$0.6 for the next quarter and -$2.51 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.56 while analysts give the company a high EPS estimate of -$0.51. Comparatively, EPS for the current quarter was -$0.72 a year ago. Earnings per share for the fiscal year are expected to increase by 40.76%, and -14.98% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Enliven Therapeutics Inc (ELVN) as a “Strong Buy” at a consensus score of 1.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ELVN, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on March 29, 2023, with the firm’s price target at $27.
